Intro [00:00:04]:
Welcome to 340B Insight from 340B Health.

David Glendinning [00:00:11]:
Hello from Washington, D.C. and welcome back to 340B

David Glendinning [00:00:15]:
Insight, the podcast about the 340B drug pricing program.

David Glendinning [00:00:19]:
I'm your host David Glendinning with 340B Health.

David Glendinning [00:00:23]:
Our guest today is 340B Health President and CEO

David Glendinning [00:00:26]:
Maureen Testoni. We speak with Maureen regularly

David Glendinning [00:00:30]:
and wanted to have her back on the show to give us a year end

David Glendinning [00:00:34]:
wrap up of all the developments in the 340B world.

David Glendinning [00:00:38]:
So here's that conversation. Today we

David Glendinning [00:00:41]:
are speaking again with 340B Health President and CEO

David Glendinning [00:00:45]:
Maureen Testoni. Maureen, thank you for making the time to

David Glendinning [00:00:49]:
be with us. And welcome back to 340B Insight.

Maureen Testoni [00:00:52]:
Thank you, David. I really appreciate the opportunity.

David Glendinning [00:00:54]:
It is December now, believe it or not, and you were

David Glendinning [00:00:58]:
last on the show in late September. What has been

David Glendinning [00:01:02]:
happening in 340B since then?

Maureen Testoni [00:01:04]:
I think the biggest issue in 340B has been a number

Maureen Testoni [00:01:07]:
of drug maker proposals to turn

Maureen Testoni [00:01:10]:
340B into a rebate. Other issues

Maureen Testoni [00:01:14]:
are that we're really focusing on are litigation

Maureen Testoni [00:01:17]:
around state contract pharmacy laws. There

Maureen Testoni [00:01:20]:
was also the first release of its

Maureen Testoni [00:01:24]:
kind by a state that had

Maureen Testoni [00:01:27]:
imposed certain reporting requirements on 340B hospitals.

Maureen Testoni [00:01:31]:
And that is something else that's new and I think

Maureen Testoni [00:01:35]:
important to understand.

David Glendinning [00:01:38]:
Let's start with the rebates. As I know that's been such a big deal

David Glendinning [00:01:41]:
for the 340B community and you just called it the number one concern at this

David Glendinning [00:01:45]:
point. Listeners of the show will know that Johnson and

David Glendinning [00:01:49]:
Johnson paused implementation of its rebate model

David Glendinning [00:01:52]:
after HRSA threatened strong enforcement actions. What

David Glendinning [00:01:56]:
is the latest on that issue?

Maureen Testoni [00:01:58]:
Johnson and Johnson has now sued hrsa. They're essentially saying that

Maureen Testoni [00:02:01]:
HRSA does not have the authority to block a rebate model.

Maureen Testoni [00:02:05]:
And since then, we're also seeing three other

Maureen Testoni [00:02:08]:
manufacturers come out saying that they

Maureen Testoni [00:02:12]:
want to do a rebate proposal. Bristol Myers,

Maureen Testoni [00:02:16]:
Squibb and Lilly have also sued

Maureen Testoni [00:02:19]:
HRSA, saying that they don't have authority to stop

Maureen Testoni [00:02:23]:
a rebate model. And both manufacturers want to impose a rebate

Maureen Testoni [00:02:27]:
model. And then Sanofi announced that it

Maureen Testoni [00:02:30]:
was going to go forward and impose a rebate model effective

Maureen Testoni [00:02:35]:
January 6th. So we'll see if

Maureen Testoni [00:02:38]:
that goes forward there. But that is something that is obviously very concerning

Maureen Testoni [00:02:42]:
because of the short date.

David Glendinning [00:02:46]:
And let's talk about some of the concerns that the

David Glendinning [00:02:50]:
340B community has. What are some of those main concerns about

David Glendinning [00:02:53]:
340B rebates when it comes to hospitals?

Maureen Testoni [00:02:57]:
Well, sticking with Sanofi, you know, they were,

Maureen Testoni [00:03:01]:
Sanofi was very explicit about

Maureen Testoni [00:03:04]:
the rules that they're gonna oppose before they would

Maureen Testoni [00:03:07]:
approve a 340B rebate for a drug. And it's

Maureen Testoni [00:03:11]:
very concerning because what Sanofi is saying is that we're gonna

Maureen Testoni [00:03:15]:
impose our own as to which

Maureen Testoni [00:03:18]:
individuals 340B hospitals can deem to

Maureen Testoni [00:03:22]:
be to qualify for 340B. And the rules that they're

Maureen Testoni [00:03:25]:
imposing are clearly intended to reduce

Maureen Testoni [00:03:29]:
the number of patients that hospitals can consider to be patients

Maureen Testoni [00:03:33]:
for 340B purposes. So this would essentially reduce the

Maureen Testoni [00:03:37]:
number of drugs that the company would have to offer a 340b

Maureen Testoni [00:03:41]:
discount on. Some of the things that they are

Maureen Testoni [00:03:44]:
doing is they are requiring

Maureen Testoni [00:03:47]:
that patients have been seen at the covered entity

Maureen Testoni [00:03:51]:
within two years. That is a rule that does not

Maureen Testoni [00:03:55]:
exist anywhere under HRSA's compliance

Maureen Testoni [00:03:58]:
policies. They are requiring that the

Maureen Testoni [00:04:02]:
prescription be directly linked to the type

Maureen Testoni [00:04:06]:
of medical care, to an actual service that the individual has

Maureen Testoni [00:04:10]:
received at the covered entity. And yet we

Maureen Testoni [00:04:14]:
all know that under 340 rules

Maureen Testoni [00:04:18]:
there can be follow up care, there can be referrals, referrals.

Maureen Testoni [00:04:21]:
HRSA does not make that tight a limit as to when

Maureen Testoni [00:04:24]:
340B can be used. They have

Maureen Testoni [00:04:28]:
rules around hospitals only using

Maureen Testoni [00:04:32]:
prescribers that are employed by the hospital or

Maureen Testoni [00:04:37]:
have some other type of affiliation which is really not spelled out what

Maureen Testoni [00:04:40]:
that affiliation would need to look like. They're requiring various

Maureen Testoni [00:04:44]:
types of patient encounter data to be able to make some of

Maureen Testoni [00:04:48]:
these determinations. And that is just

Maureen Testoni [00:04:51]:
very concerning that they would try to impose

Maureen Testoni [00:04:55]:
their own rules like this under a rebate program.

Maureen Testoni [00:04:59]:
And I think that's a big concern that hospitals have.

David Glendinning [00:05:02]:
And I will mention that there's no public response to the

David Glendinning [00:05:06]:
Sanofi plan from HRSA yet and no lawsuit from the company though, that

David Glendinning [00:05:09]:
says of when we are speaking today. We know things can change quickly in

David Glendinning [00:05:13]:
this area. So that covers Sanofi. What do we know at this point

David Glendinning [00:05:17]:
about the other rebate models that drug makers

David Glendinning [00:05:21]:
are pushing?

Maureen Testoni [00:05:22]:
We don't have a lot of details really on the other rebate models.

Maureen Testoni [00:05:25]:
We know that Johnson and Johnson plan to use the same

Maureen Testoni [00:05:29]:
vendor, Beacon, for processing its

Maureen Testoni [00:05:32]:
rebates. So they do have information on the types of claims,

Maureen Testoni [00:05:36]:
some of the claims data that they're looking for, but they don't really

Maureen Testoni [00:05:40]:
provide all the details as to how they're going

Maureen Testoni [00:05:44]:
to use that information to determine whether to approve

Maureen Testoni [00:05:47]:
a claim. They just say we're going to get this data

Maureen Testoni [00:05:51]:
and we will then determine whether to approve. But they're

Maureen Testoni [00:05:55]:
not really saying what you would have to show for sure

Maureen Testoni [00:06:00]:
to make sure that your claim would be approved. That's a distinction

Maureen Testoni [00:06:03]:
with Sanofi going into a lot more detail about the new rules

Maureen Testoni [00:06:07]:
that they are imposing. Similarly with

Maureen Testoni [00:06:11]:
Lilly and with Bristol Myers Scopes. We don't

Maureen Testoni [00:06:14]:
know exactly what the rules are that they are proposing.

Maureen Testoni [00:06:18]:
And that is obviously concerning for hospitals because now

Maureen Testoni [00:06:22]:
if rebates were to go forward, it's all in the hands of the

Maureen Testoni [00:06:25]:
manufacturers as to whether and when you would receive the

Maureen Testoni [00:06:29]:
340B discount that you know you are supposed to be getting that they are obligated

Maureen Testoni [00:06:33]:
to provide you under the 340B statute.

David Glendinning [00:06:35]:
Why are drug companies saying they need to impose

David Glendinning [00:06:39]:
rebates on 340B hospitals? What reasons are they giving in all of

David Glendinning [00:06:43]:
these notices and lawsuits they've been filing?

Maureen Testoni [00:06:45]:
Manufacturers have been claiming that 340B has grown, you

Maureen Testoni [00:06:49]:
know, beyond what it is supposed to grow. So they are concerned

Maureen Testoni [00:06:53]:
about the fact that a high number of their drugs are being subject to

Maureen Testoni [00:06:57]:
340B discounts than there were in 1992 when

Maureen Testoni [00:07:00]:
340B was enacted. But the truth is

Maureen Testoni [00:07:04]:
healthcare has moved from the inpatient setting in the hospital to the

Maureen Testoni [00:07:07]:
outpatient setting. So many more drugs are available in the

Maureen Testoni [00:07:11]:
outpatient setting than there were in 1992. And, you

Maureen Testoni [00:07:15]:
know, we have, you know, people aren't necessarily even getting certain heart

Maureen Testoni [00:07:18]:
surgeries anymore because they can rely on certain specialty drugs

Maureen Testoni [00:07:22]:
to address that. So it's not a surprise they are also claiming

Maureen Testoni [00:07:26]:
that three 340B covered entities are not always following the rules

Maureen Testoni [00:07:30]:
around 340B and that they believe, you know,

Maureen Testoni [00:07:33]:
HRSA isn't doing a good job with that.

Maureen Testoni [00:07:37]:
And that's, you know, you can see this with, especially with the types of rules

Maureen Testoni [00:07:40]:
that Sanofi is trying to put into place around, you know,

Maureen Testoni [00:07:44]:
does the individual patient really qualify for

Maureen Testoni [00:07:48]:
340B? But the truth is, you, the

Maureen Testoni [00:07:51]:
Sanofi does not going to be able to figure that out. You know, this is

Maureen Testoni [00:07:55]:
something you have to look at medical charts. When HRSA goes in and audits

Maureen Testoni [00:07:59]:
covered entities, they are looking at the

Maureen Testoni [00:08:02]:
charts, at the patient charts to make that determination as

Maureen Testoni [00:08:06]:
to whether the hospitals are appropriately using

Maureen Testoni [00:08:09]:
340B for the right kinds of patients. And in recent

Maureen Testoni [00:08:13]:
years, we're seeing findings in that area against

Maureen Testoni [00:08:17]:
hospitals to be very, very low. So there is just no

Maureen Testoni [00:08:20]:
evidence of widespread abuse by

Maureen Testoni [00:08:24]:
hospitals in the area of whether or not patients really

Maureen Testoni [00:08:28]:
qualify for 340 B. And another issue that they bring up

Maureen Testoni [00:08:31]:
is something that's called a duplicate discount. It's a little

Maureen Testoni [00:08:35]:
confusing. It means that if an entity

Maureen Testoni [00:08:39]:
buys a drug at the 340b price, then the Medicaid

Maureen Testoni [00:08:42]:
agency should not be requesting a

Maureen Testoni [00:08:46]:
rebate from the manufacturer for that drug. And when

Maureen Testoni [00:08:50]:
you look at the findings from HRSA audits, there is

Maureen Testoni [00:08:54]:
nothing in any of those findings to suggest that there's widespread

Maureen Testoni [00:08:58]:
duplicate discounts going on. Because the fact is, HRSA

Maureen Testoni [00:09:02]:
does not check to see whether or not a

Maureen Testoni [00:09:06]:
state actually sought a rebate and whether or not

Maureen Testoni [00:09:09]:
the manufacturer actually paid it for a 340B drug. The

Maureen Testoni [00:09:13]:
only thing that HRSA does when they go into their

Maureen Testoni [00:09:17]:
audit is identify whether the hospital

Maureen Testoni [00:09:21]:
complied with duplicate discount requirements. And those

Maureen Testoni [00:09:24]:
requirements are that the hospital has to put his billing number up on

Maureen Testoni [00:09:28]:
HRSA's website. And that way states can use that billing number to

Maureen Testoni [00:09:32]:
make, to exclude any of the drug claims that

Maureen Testoni [00:09:36]:
are for Medicaid patients. So hospitals,

Maureen Testoni [00:09:40]:
you know, if they transpose, you know, a couple of numbers in

Maureen Testoni [00:09:44]:
their, when they put it up on the website, they'll get a finding that says

Maureen Testoni [00:09:46]:
duplicate discounts. And in fact, many hospitals are able

Maureen Testoni [00:09:50]:
to get the duplicate discount finding change to, you

Maureen Testoni [00:09:54]:
know, a web site error finding because they're able to get their

Maureen Testoni [00:09:57]:
Medicaid agency to say, no, we don't even use HRSA's website. We have our

Maureen Testoni [00:10:01]:
own process for identifying 340B claims,

Maureen Testoni [00:10:05]:
and we can confirm we have not made any requests to the manufacturers for

Maureen Testoni [00:10:08]:
rebates on this entity's claims. So when we're seeing

Maureen Testoni [00:10:12]:
findings made by the government on duplicate discounts, it's really important to understand

Maureen Testoni [00:10:16]:
that does not in any way, shape or form mean that a duplicate discount actually

Maureen Testoni [00:10:20]:
occurred. And we have not seen real data

Maureen Testoni [00:10:23]:
produced by these manufacturers to demonstrate that,

Maureen Testoni [00:10:27]:
that this is actually a serious issue.

David Glendinning [00:10:30]:
Our listeners will be eager to know where this whole

David Glendinning [00:10:34]:
rebate debate leads for them. So what is

David Glendinning [00:10:37]:
340B Health doing to advocate against these rebates?

Maureen Testoni [00:10:41]:
One, now that it's in the federal courts, we will again be

Maureen Testoni [00:10:45]:
very involved with the litigation. In previous litigation

Maureen Testoni [00:10:49]:
that has been filed by manufacturers against the government,

Maureen Testoni [00:10:52]:
we have always submitted amicus briefs,

Maureen Testoni [00:10:56]:
sometimes on our own, sometimes we work with other associations. So we

Maureen Testoni [00:11:00]:
are currently in discussions with our legal counsel to determine the best

Maureen Testoni [00:11:04]:
way to interact in these cases, whether

Maureen Testoni [00:11:07]:
it is by actually intervening, which would, if we got permission to

Maureen Testoni [00:11:11]:
intervene, that would allow us to make arguments directly

Maureen Testoni [00:11:15]:
to the judge. So it gives us a little bit more of a presence

Maureen Testoni [00:11:19]:
than an amicus. However, I will mention this is

Maureen Testoni [00:11:22]:
likely to take a While this is unlikely to be a fast moving

Maureen Testoni [00:11:26]:
lawsuit, so there is, you know, there still is some time

Maureen Testoni [00:11:30]:
before the court is really going to require any briefing on this

Maureen Testoni [00:11:34]:
case. You know, I will also mention that the ira,

Maureen Testoni [00:11:38]:
the legislation about that includes provisions to allow

Maureen Testoni [00:11:41]:
Medicare to negotiate lower prices for drug is going

Maureen Testoni [00:11:45]:
to be implemented in, you know, in the coming year.

Maureen Testoni [00:11:49]:
And manufacturers are going to be submitting within a few months their

Maureen Testoni [00:11:52]:
plans for implementing how they're

Maureen Testoni [00:11:56]:
going to make the Medicare prices available. And

Maureen Testoni [00:12:00]:
it's been controversial as to how 340

Maureen Testoni [00:12:04]:
is going to fit into that. Covered entities

Maureen Testoni [00:12:08]:
are entitled to the 340b price regardless of what the

Maureen Testoni [00:12:11]:
Medicare price is. But the process that the government

Maureen Testoni [00:12:15]:
is using to implement it does conflict with

Maureen Testoni [00:12:18]:
340B in some ways. It is absolutely

Maureen Testoni [00:12:22]:
doable to do what the government is proposing. But the

Maureen Testoni [00:12:25]:
manufacturers believe that it is having a

Maureen Testoni [00:12:29]:
rebate program would make it easier for them to

Maureen Testoni [00:12:32]:
comply with the, with the government's, you

Maureen Testoni [00:12:36]:
know, process. So I think it's important that we

Maureen Testoni [00:12:39]:
have a lot of advocacy going on about the fact this is not

Maureen Testoni [00:12:43]:
needed. Rebates are not needed for the IRA as

Maureen Testoni [00:12:47]:
well. I wrote about this in a, in a Wall Street Journal essay

Maureen Testoni [00:12:51]:
recently. The IRA was never intended to transform 340B

Maureen Testoni [00:12:55]:
into a rebate system. The government has refused to require

Maureen Testoni [00:12:58]:
340B rebates either for the Medicare

Maureen Testoni [00:13:02]:
program, the drugs that are subject to the negotiation, or otherwise

Maureen Testoni [00:13:06]:
for 340B drugs. And drug makers absolutely

Maureen Testoni [00:13:10]:
have other avenues to comply with the IRA

Maureen Testoni [00:13:13]:
and 340B which the Centers for

Maureen Testoni [00:13:17]:
Medicare and Medicaid Services is saying that they are

Maureen Testoni [00:13:20]:
exploring as well. So it's important that

Maureen Testoni [00:13:24]:
we are, you know, advocating against rebates for 340B

Maureen Testoni [00:13:28]:
but also in the context of the Medicare

Maureen Testoni [00:13:31]:
negotiation scheme.

David Glendinning [00:13:33]:
At the top of the show you mentioned the contract

David Glendinning [00:13:36]:
pharmacy litigation over state laws. What is the

David Glendinning [00:13:40]:
latest status on those?

Maureen Testoni [00:13:42]:
So far we have seen a number of lawsuits from

Maureen Testoni [00:13:45]:
manufacturers and from their association

Maureen Testoni [00:13:48]:
pharmacy. And a lot of those are we're arguing

Maureen Testoni [00:13:52]:
that, you know, the states just do not have the authority to make

Maureen Testoni [00:13:56]:
any rules around 340 because 340B is a federal law. And so

Maureen Testoni [00:13:59]:
far they have lost those. So that has been

Maureen Testoni [00:14:03]:
great. However, there are some manufacturers are making

Maureen Testoni [00:14:06]:
new arguments around very technical

Maureen Testoni [00:14:10]:
issues about whether the providers retain

Maureen Testoni [00:14:13]:
title when the drugs are transferred to the contract pharmacy and some

Maureen Testoni [00:14:17]:
other issues. We are very involved in these cases.

Maureen Testoni [00:14:21]:
Cases. We do amicus briefs for all of these lawsuits along

Maureen Testoni [00:14:24]:
with a couple of others of the hospital associations and

Maureen Testoni [00:14:28]:
State associations. But we are also working

Maureen Testoni [00:14:31]:
closely with some of the attorneys that are working on some of

Maureen Testoni [00:14:35]:
these cases to assist with

Maureen Testoni [00:14:39]:
the more technical analysis about this. Whether there is

Maureen Testoni [00:14:43]:
any merit to some of these arguments

Maureen Testoni [00:14:47]:
that the manufacturers are making, I do not believe there is. But

Maureen Testoni [00:14:50]:
that is the case that we are really building up right now and that I

Maureen Testoni [00:14:54]:
expect to be the big issue in the coming year.

David Glendinning [00:14:57]:
You also said there's a new 340B report out,

David Glendinning [00:15:00]:
and our regular listeners will know that is coming from

David Glendinning [00:15:04]:
Minnesota, the land of 10,000 lakes. What does

David Glendinning [00:15:07]:
that report say?

Maureen Testoni [00:15:10]:
So this Minnesota report,

Maureen Testoni [00:15:15]:
it comes out of legislation that was

Maureen Testoni [00:15:19]:
passed in 2023 that

Maureen Testoni [00:15:22]:
requires covered any

Maureen Testoni [00:15:25]:
to submit certain information

Maureen Testoni [00:15:29]:
to the state. And one of the things that they

Maureen Testoni [00:15:33]:
required is that covered entities report the

Maureen Testoni [00:15:37]:
prices, you know, they're spending on 340B drugs

Maureen Testoni [00:15:40]:
and then how much they received from insurers, you know,

Maureen Testoni [00:15:44]:
in payment for those drugs. And that number, the number that they

Maureen Testoni [00:15:48]:
released was 630 million.

Maureen Testoni [00:15:52]:
Now, that is a calculation that we are

Maureen Testoni [00:15:55]:
really take issue with because it really overstates

Maureen Testoni [00:15:59]:
the value of 340B. 630 million is not the value

Maureen Testoni [00:16:03]:
of 340B. For the hospitals in Minnesota,

Maureen Testoni [00:16:07]:
the value is going to be lower than that. And that's because all that

Maureen Testoni [00:16:11]:
340B does is it gives a discount on the

Maureen Testoni [00:16:14]:
drug. But hospitals that aren't in 340B don't

Maureen Testoni [00:16:18]:
buy the drug at the sticker price. It's called wholesale acquisition cost,

Maureen Testoni [00:16:22]:
which is like the car sticker price. Nobody buys it at that. And so if

Maureen Testoni [00:16:25]:
they weren't in 340B, they would still be getting discounts on drugs by

Maureen Testoni [00:16:29]:
purchasing through their group purchasing organization. So the

Maureen Testoni [00:16:33]:
630 millions is a number that may apply.

Maureen Testoni [00:16:37]:
If everybody was purchasing their drugs at WAC and the

Maureen Testoni [00:16:41]:
only people that got a discount was 340B.

Maureen Testoni [00:16:44]:
So what you really want to do, if you were trying to see what the

Maureen Testoni [00:16:47]:
benefit of 340B is, is you would compare the GPO

Maureen Testoni [00:16:51]:
prices that hospitals have against what they're paying for 340B. So if

Maureen Testoni [00:16:55]:
the 340B price is 80, the GPO price is

Maureen Testoni [00:16:58]:
100, and the sticker price, the WACC price is

Maureen Testoni [00:17:01]:
200, then the real difference isn't going to be between

Maureen Testoni [00:17:05]:
that $80 and the 200. It's going to be between the $80

Maureen Testoni [00:17:09]:
for 340B and the 100 for the GPO. But even looking at

Maureen Testoni [00:17:13]:
that 630 number, it's important to understand

Maureen Testoni [00:17:17]:
what that number means in terms of how much is spent on

Maureen Testoni [00:17:21]:
patient care by Minnesota hospitals overall? And that

Maureen Testoni [00:17:24]:
is $15 billion on patient care

Maureen Testoni [00:17:28]:
last year. And about $770 million

Maureen Testoni [00:17:32]:
was spent on uncompensated, unreimbursed care. So

Maureen Testoni [00:17:36]:
that is care where the hospital received no

Maureen Testoni [00:17:40]:
compensation. You know, people that just did not have insurance or

Maureen Testoni [00:17:44]:
care where they received, you know, less than their

Maureen Testoni [00:17:47]:
costs, such as, you know, Medicaid, which

Maureen Testoni [00:17:50]:
notoriously pays much less than the cost. And then if you

Maureen Testoni [00:17:54]:
were to add to that number the underpayment that hospitals

Maureen Testoni [00:17:58]:
receive from Medicare, I personally believe that number would

Maureen Testoni [00:18:01]:
be closer to a billion dollars. And so without

Maureen Testoni [00:18:05]:
340B, it'd be very difficult for hospitals maintain that

Maureen Testoni [00:18:08]:
level of.

David Glendinning [00:18:09]:
Care if it's the end of the year. We here at 340B Health

David Glendinning [00:18:13]:
are preparing for the upcoming 340B Coalition Winter Conference.

David Glendinning [00:18:17]:
What are you most looking forward to for that meeting?

Maureen Testoni [00:18:19]:
I really love our conferences. It's just such a Great so

Maureen Testoni [00:18:23]:
many 340B minds in one place is just is

Maureen Testoni [00:18:27]:
really fun for me. And you know, this year our conference will be in San

Maureen Testoni [00:18:30]:
Diego. It'll be in February 24th to the 26th.

Maureen Testoni [00:18:34]:
I really encourage everybody who is really interested in

Maureen Testoni [00:18:37]:
340B to attend. We do a lot of

Maureen Testoni [00:18:41]:
sessions on compliance issues, including the

Maureen Testoni [00:18:45]:
inflation Reduction act, the Medicare negotiation policy that I

Maureen Testoni [00:18:49]:
talked about earlier Sessions on optimizing 340B on how

Maureen Testoni [00:18:52]:
to stay compliant. On 340B, we will have sessions to

Maureen Testoni [00:18:56]:
sort of what to expect in Washington with the new administration

Maureen Testoni [00:19:00]:
and the new Congress. And our featured speaker will be a

Maureen Testoni [00:19:03]:
Harvard professor that's going to be discussing the future of

Maureen Testoni [00:19:07]:
healthcare economics. So it's a great way to network with other

Maureen Testoni [00:19:10]:
340B people. It's a great way to learn about,

Maureen Testoni [00:19:14]:
learn new strategies that your peers may be using around

Maureen Testoni [00:19:18]:
340B. You know, sharing best practices, learning new ideas,

Maureen Testoni [00:19:22]:
talking about 340B advocacy. Early Bird registration

Maureen Testoni [00:19:25]:
is going on right now and it's going to end December 20th.

Maureen Testoni [00:19:29]:
So I really encourage people to sign up before then so you can

Maureen Testoni [00:19:33]:
secure your discounted rate.

David Glendinning [00:19:34]:
And we will be sure to put that link and a few other links of

David Glendinning [00:19:37]:
interest in the show notes so our listeners don't need to venture far to find

David Glendinning [00:19:41]:
them. Maureen, thank you for taking the time during the

David Glendinning [00:19:44]:
pre holiday rush to be with us today. We all appreciate it.

Maureen Testoni [00:19:48]:
Well, thank you so much for having me. I really appreciate it. Dave.

David Glendinning [00:19:50]:
We thank Maureen Testoni again for being with us today and

David Glendinning [00:19:54]:
all year long. And we thank you, our loyal listeners

David Glendinning [00:19:58]:
for joining us during this season of 340B Insight. This

David Glendinning [00:20:02]:
is our last episode of 2024 and we will be taking a

David Glendinning [00:20:05]:
short break while we prepare for another full season of episodes

David Glendinning [00:20:09]:
in 2025. Please keep those ideas coming

David Glendinning [00:20:13]:
for episodes and guests. You can always email us at

David Glendinning [00:20:17]:
podcast340bhealth.org have

David Glendinning [00:20:20]:
a joyous, peaceful holiday season and a happy, healthy

David Glendinning [00:20:24]:
new Year. We will be back in January. In the meantime, as

David Glendinning [00:20:27]:
always, thanks for listening and be well.

Outro [00:20:34]:
Thanks for listening to 340B Insight. Subscribe and rate

Outro [00:20:38]:
us on Apple Podcasts, Google Play, Spotify, or wherever

Outro [00:20:42]:
you listen to podcasts. For more information, visit our

Outro [00:20:46]:
website@340bpodcast.org you can also

Outro [00:20:49]:
follow us on Twitter behealth and submit a question or

Outro [00:20:53]:
idea to the show by emailing us at

Outro [00:20:56]:
podcast@340bhealth.org.